Shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) were up 3.2% during mid-day trading on Friday . The company traded as high as $152.50 and last traded at $151.51, with a volume of 228,197 shares. The stock had previously closed at $146.82.

A number of analysts have recently issued reports on ICPT shares. Morgan Stanley reiterated a “sell” rating and set a $80.00 target price on shares of Intercept Pharmaceuticals in a report on Friday, August 5th. Goldman Sachs Group Inc. boosted their target price on Intercept Pharmaceuticals from $114.00 to $128.00 and gave the stock a “neutral” rating in a report on Tuesday, May 31st. Cantor Fitzgerald started coverage on Intercept Pharmaceuticals in a report on Wednesday, July 6th. They set a “sell” rating and a $58.00 target price for the company. Robert W. Baird reiterated an “outperform” rating and set a $332.00 target price on shares of Intercept Pharmaceuticals in a report on Wednesday, June 15th. Finally, Laidlaw cut Intercept Pharmaceuticals from a “buy” rating to a “sell” rating and decreased their price target for the stock from $345.00 to $105.00 in a report on Friday, August 5th. Five analysts have rated the stock with a sell rating, five have issued a hold rating and ten have issued a buy rating to the company’s stock. Intercept Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $177.67.

The company has a 50-day moving average price of $159.42 and a 200 day moving average price of $143.90. The company’s market capitalization is $3.73 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($3.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($3.69) by $0.55. The company had revenue of $5.52 million for the quarter, compared to analyst estimates of $1.72 million. The business’s revenue was up 1140.4% on a year-over-year basis. During the same period in the prior year, the company posted ($1.99) EPS. Analysts anticipate that Intercept Pharmaceuticals Inc. will post ($16.31) earnings per share for the current year.

In other Intercept Pharmaceuticals news, insider Lisa Bright sold 246 shares of the firm’s stock in a transaction that occurred on Thursday, August 25th. The stock was sold at an average price of $159.00, for a total value of $39,114.00. Following the sale, the insider now owns 18,460 shares of the company’s stock, valued at approximately $2,935,140. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Mark Pruzanski sold 714 shares of the firm’s stock in a transaction that occurred on Tuesday, July 5th. The shares were sold at an average price of $145.11, for a total value of $103,608.54. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Intercept Pharmaceuticals stock. BlackRock Advisors LLC raised its position in shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) by 5.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 125,274 shares of the biopharmaceutical company’s stock after buying an additional 6,461 shares during the period. BlackRock Advisors LLC owned 0.51% of Intercept Pharmaceuticals worth $18,710,000 at the end of the most recent quarter.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.